Insulin Glargine Recall; Obesity & Endometrial Cancer; Red Light for Testosterone?

Mylan Pharmaceuticals voluntarily recalled one batch of unbranded insulin glargine injection 100 units/mL (insulin glargine-yfgn) due to a possible missing label, the FDA announced.

Infertility was tied to a 16% higher risk for future heart failure and a 27% higher risk of heart failure with preserved ejection fraction, according to a study of postmenopausal women. (Journal of the American College of Cardiology)

A Mendelian randomization study found a causal link between obesity and endometrial cancer risk. (BMC Medicine)

The U.S. Preventive Services Task Force is still recommending against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal persons, in a new draft recommendation statement. The document is open for public comments through May 16.

In a treatment study of diabetic ketoacidosis, a hospital-wide subcutaneous insulin protocol was associated with reduced hospital resource utilization but not with any increased risk of hypoglycemia. (JAMA Network Open)

Though it is an unproven treatment, Tucker Carlson recently promoted red light therapy to increase testosterone levels in men. (Insider)

In order to bolster access to fertility services, the Department of Veterans Affairs is dropping copays for birth control prescriptions and fertility services in 2023. (Military.com)

In a study of patients enrolled in the Action to Control Cardiovascular Risk in Diabetes lipid trial (ACCORD Lipid), fenofibrate significantly reduced the risk of heart failure hospitalizations and cardiovascular death in those with type 2 diabetes treated with the statin simvastatin. (Diabetes Care)